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Abstract
Background: The pleiotropic pro-inflammatory cytokine Interleukin (IL)-18 has been proposed to play a role in
schizophrenia, since elevated circulating levels of its protein and altered frequencies of genetic variants in its
molecular system are reported in schizophrenic patients.
Methods: We analyzed 77 patients with schizophrenia diagnosis (SCZ) and 77 healthy control subjects (HC) for
serum concentration of both IL-18 and its natural inhibitor, the IL-18 binding protein (IL-18BP).
Results: We confirmed that serum levels of total IL-18 are significantly increased in SCZ, as compared to HC.
However, due to a highly significant increase in levels of circulating IL-18BP in SCZ, as compared to HC, the levels
of free, bioactive IL-18 are not significantly different between the two groups. In addition, the relationships between
the levels of IL-18 and its inhibitor, as well as between the two molecules and age appear dissimilar for SCZ and
HC. In particular, the elevated levels of IL-18BP, likely a consequence of the body’s attempt to counteract the early
prominent inflammation which characterizes schizophrenia, are maintained in earlier and later stages of the disease.
However, the IL-18BP elevation appears ineffective to balance the IL-18 system in younger SCZ patients, while in
older patients the levels of circulating bioactive IL-18 are comparable to those of HC, if not lower.
Conclusions: In conclusion, these findings indicate that the IL-18 system is perturbed in schizophrenia, supporting
the idea that this pro-inflammatory cytokine might be part of a pathway of genetic and environmental
components for vulnerability to the disease.
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Background
Interleukin (IL)-18 is a pleiotropic pro-inflammatory
molecule acting as a potent promoter of chronic inflam-
mation, autoimmunity and age-dependent inflammatory
processes [1,2]. Recently, IL-18 has been found to play a
diverse array of functions in non-immune tissues as the
central nervous system [3], and its abnormal expression
has been observed both centrally and peripherally in
neuropsychiatric disorders such as Alzheimer’s disease
and stroke [4,5].
The bioactivity of IL-18 is modulated by a secreted
binding protein (IL-18BP) with neutralizing abilities,
which binds IL-18 with high affinity (Kd = 0.4 nM) and
prevents its interaction with the receptor [6,7]. IL-18BP is
constitutively present in the serum of healthy humans at
molar excess when compared with IL-18 [8], and it
appears to be modulated during the life. In fact, since IL-
18 participates in fundamental inflammatory processes
that increase during the aging process [2] and IL-18BP
serum levels tend to increase in old age with evidence of
strong increment in healthy centenarians [9], it has been
suggested that IL-18BP retains a remarkable protective
role by acting to limit the impact of age-related inflamma-
tion. In addition, IL-18BP appears to be strongly modu-
lated in pathological circumstances, as it increases with
the increase of IL-18 production in inflammatory condi-
tions [10], likely operating a negative feedback mechanism
* Correspondence: p.bossu@hsantalucia.it
1Clinical and Behavioral Neurology, IRCCS Fondazione Santa Lucia,
Via Ardeatina 306, 00179 Rome, Italy
3Department of Clinical and Behavioral Neurology, Experimental
Neuro-psychobiology Lab, IRCCS Santa Lucia Foundation, Via Ardeatina, 306,
I-00179 Rome, Italy
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2012 Palladino et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Palladino et al. Journal of Neuroinflammation 2012, 9:206
http://www.jneuroinflammation.com/content/9/1/206
that is able to reduce IL-18-elicited immune responses
[11].
Schizophrenia is a familiar multigenic disorder with
probable neurodevelopmental origins, characterized by a
wide range of psychotic symptoms that appear in adoles-
cence and persist throughout the life of affected indivi-
duals. Among the several possible hypotheses formulated
to explain the genesis of schizophrenia, immune system
vulnerability is one of the most recognized [12,13]. A pos-
sible link between immune function changes and schizo-
phrenia development is the stimulation of cytokine
response. This has prompted renewed interest in cytokines
as markers of immune imbalance in schizophrenia and
cytokine-centered hypotheses of schizophrenia pathogen-
esis have been recently proposed [14]. In agreement with
the idea that imbalances of pro- and anti-inflammatory
cytokines may contribute to the onset of psychotic symp-
toms and the progressive loss of brain tissue in schizo-
phrenia, IL-18 has been proposed to be connected to this
disorder. In particular, five polymorphisms in genes related
to the IL-18 pathway, including IL-18 receptor genes, have
been associated with schizophrenia [15] and some variants
of the IL-18 gene have been recently related to the devel-
opment of schizophrenia symptoms [16]. Furthermore,
levels of IL-18 circulating protein are higher in affected
patients than in controls [17,18] and are associated with
the psychopathology of schizophrenia [19].
However, the IL-18 biology in schizophrenia is still un-
clear and no data are available on the relationship be-
tween IL-18 and IL-18BP in affected individuals.
Therefore, in the present study we analyzed IL-18 and
IL-18BP peripheral levels in subjects with schizophrenia




Seventy-seven SCZ diagnosed according to the Diagnostic
and Statistical Manual of Mental Disorders-IV edition
(DSM-IV) as previously reported [20] were recruited from
outpatient clinics in Central Italy. Seventy-seven healthy
control subjects (HC) were recruited in the same geo-
graphic area and matched with the SCZ for age and gender,
as summarized in Table 1. Exclusion criteria were: 1) treat-
ment with anti-inflammatory or immunosuppressive medi-
cation; 2) overt infectious disease or auto-immune disease;
3) history of alcohol or drug dependence or traumatic head
injury; 4) any past or present major medical or neurological
illness. This research was carried out with the ethical ap-
proval of Santa Lucia Foundation institutional review board.
Written informed consent was obtained from each subject
after giving subjects a complete description of the study.
All patients were receiving stable oral doses of one or
more atypical antipsychotic drugs such as risperidone,
quetiapine, and olanzapine. Antipsychotic dosages were
converted to estimated equivalent dosages of olanzapine.
Serum and IL-18/IL-18BP measurement
Serum samples were obtained from all subjects by cen-
trifugation of clotted blood, and aliquots were stored at
−80°C until cytokine assays were performed.
Total IL-18, corresponding to the total amount of free
IL-18 and IL-18 bound to IL-18BP, was determined by
enzyme-linked immunosorbent assay (ELISA), using anti-
bodies unable to distinguish between the free and the
bound form of IL-18. More in detail, coating antibody
(clone 125–2 H), detecting antibody (clone 159-12B) and
standard human recombinant IL-18, were used (MBL, Na-
goya, Japan). IL-18BP was measured using commercial
ELISA (R&D Systems Minneapolis, MN, USA) specific for
IL-18BPa, the prevalent isoform in humans, in accordance
with the manufacturer’s instructions. The limit of detec-
tion for both assays was 12.5 pg/mL. Concentrations of
free IL-18, namely unbound to IL-18BP, resulted from cal-
culation based on the law of mass action, considering 1:1
stoichiometry in the complex of IL-18 and IL-18BP and a
dissociation constant (Kd) of 0.4 nM, as elsewhere
reported in more detail [10,21].
Statistical analysis
In order to detect statistically significant differences,
comparisons between continuous variables were made
using the Student’s t test. Pearson’s correlation coeffi-
cient was used to assess the relationships between con-
tinuous variables. The level of statistical significance was
defined as P <0.05. GraphPad (Prism Version 4, San
Diego, CA) software was used for statistical analyses.
Results
Serum levels of IL-18/IL-18BP
The concentration of both IL-18 and IL-18BP was evalu-
ated for the serum of each subject. In order to define the
Table 1 Clinical and biological characteristics of
schizophrenic and healthy control subjects
Characteristics Healthy control
subjects
(HC, n = 77)
Schizophrenic
patients
(SCZ, n = 77)
Males/Females (n) 49/28 49/28
Age (years ± SEM) 41.8 ± 1.4 40.9 ± 1.3a
Serum IL-18 (pg/ml ± SEM) 382 ± 16.5 518.2 ± 22.1b
Serum IL-18BP (ng/ml ± SEM) 4.9 ± 0.2 9.8 ± 0.4b
Serum free IL-18 (pg/ml ± SEM) 239.3 ± 9.8 253.6 ± 12.1a
Disease onset age (years ± SEM) - 25.4 ± 1.1
Duration of illness (years ± SEM) - 14.9 ± 1.6
Olanzapine equivalents
(mg/day ± SEM)
- 22.3 ± 5.5
adifference is not significant versus HC; bP <0.0001 versus HC.
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levels of bioactive cytokine, free IL-18 was also calculated
on the basis of IL-18 and IL-18BP results. Mean values of
total or unbound IL-18 and its inhibitor concentration are
reported in Table 1, while individual values are reported in
the upper panels of Figure 1. Total IL-18 levels were sig-
nificantly higher in SCZ than HC (P<0.0001). Similarly,
serum levels of IL-18BP were significantly higher in SCZ
than HC (P<0.0001). Interestingly, serum levels of free,
bioactive IL-18 were not significantly different between
SCZ and HC. The levels of the three elements of IL-18
system were not significantly different between males and
females and did not correlate significantly with illness dur-
ation and antipsychotic drug dosages.
Relationship between IL-18, IL-18BP and age
In order to evaluate a possible relationship between total
IL-18 and IL-18BP levels, we first assessed the relation-
ship existing between the two immune mediators both
in SCZ and HC. A positive significant correlation was
found in SCZ (r = 0.245, P= 0.03) but not in HC.
Afterwards, given that IL-18 might participate in age-
dependent inflammation, we analyzed the direct rela-
tionship between the serum concentration of total IL-18,
IL-18BP, free IL-18 and age in all subjects. Indeed, a sig-
nificant positive correlation between serum total IL-18
levels and age was found in HC (r = 0.268; P= 0.018), but
not in SCZ. No significant correlations were observed be-
tween the levels of IL-18BP and age in both HC and
SCZ. Differently, an unexpected and highly significant in-
verse correlation was found between the serum amount
of free IL-18 and age in SCZ (r =−0.432; P <0.0001) but
not in HC.
In order to further investigate the age dependence of the
IL-18 system, we compared the changes in the levels of
IL-18-related molecules in HC and SCZ after dividing
each main group into two subgroups formed by the
youngest (≤ 30 years; HC, n= 15 and SCZ, n= 18) and the
oldest (≥50 years; HC, n= 22 and SCZ, n= 19) subjects.
As shown in the lower panels of Figure 1, SCZ showed an
increase of total IL-18, as compared to HC, in the young-
est (1.82-fold increase; P<0.0001) but not in the oldest
individuals. The levels of IL-18BP were significantly higher
in SCZ, as compared to HC, both in the youngest and the
oldest subjects, although the increase was slightly higher
in the youngest (2.2-fold increase; P<0.0001) than the old-
est (1.96-fold increase; P<0.0001) subgroup. In contrast,
the levels of free IL-18 were significantly higher in SCZ
than HC as for the subgroup of the youngest subjects
(1.48-fold increase; P=0.0006), while the biologically ac-
tive cytokine has a tendency to decrease in SCZ versus HC
in individuals with an age ≥50 years (1.24-fold decrease;
P=0.068).
Discussion
It is known that the pro-inflammatory cytokine IL-18 is
present in the circulation partly as an inactive complex
Figure 1 Concentration of IL-18, IL-18BP and free IL-18 in serum of all HC (n = 77) and SCZ (n = 77) subjects (upper panels) and in two
age subgroups of HC and SCZ subjects (lower panels), including subjects with age≤ 30 years (HC: n = 15, mean age= 24.4 ± 0.7; SCZ:
n = 18, mean age= 25.6 ± 0.7) and age≥ 50 years (HC: n = 22, mean age= 56.5 ± 1; SCZ: n = 19, mean age= 56.1 ± 1.1). Asterisks inside the
graphs indicate the significance of comparisons of SCZ vs. HC: * P< .001, ** P < .0001. HC, healthy controls; SCZ, schizophrenic patients.
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with IL-18BP and partly as free, bioactive IL-18 [6,7].
Previous studies indicate that schizophrenia is paralleled
by elevated levels of serum IL-18 without any
characterization of the active form of the cytokine
[17,18]. In the present report we assessed the levels of
both IL-18 and IL-18BP in SCZ and age- and gender-
matched HC. We confirmed that the total amount of IL-
18, including the unbound and the IL-18BP-bound form
of the cytokine, is higher in SCZ than in HC. Neverthe-
less, the main finding of this study is that the cytokine
inhibitor IL-18BP is significantly increased in the serum
of SCZ, as compared to HC. Interestingly, this elevation
is about 40% higher than that of total IL-18. Thus, the
evident increase of IL-18BP in SCZ creates a balance in
the levels of free active IL-18, which, in fact, appear
comparable between patients and HC subjects.
As a further indication of the altered modulation of IL-
18 system in schizophrenia, we found a positive correl-
ation between total IL-18 and its inhibitor only in SCZ
and not in HC. This correlation may be linked to the fact
that SCZ show, in comparison with HC, a greater range
of values in IL-18BP levels. This, together with the obser-
vation occurring in autoimmune conditions that IL-18BP
is triggered when the IL-18 response is amplified [10],
leads us to hypothesize that IL-18BP elevation in SCZ is
linked to an early and disease-dependent increase of IL-
18. Accordingly, when we compared the levels of IL-18
system molecules of SCZ and HC belonging to different
age groups, we confirmed the previous assumption that
in HC there is a trend of IL-18 to increase with age [2,9].
Conversely, this age-associated modulation of the IL-18
system appears altered in SCZ, thus strengthening the
concept of an IL-18 system perturbation associated with
the disorder. We established that in SCZ subjects, as
compared to age-matched HC, the increase of total and
free IL-18 was observable only in the youngest indivi-
duals, where the elevation of IL-18BP did not seem to
reach adequate levels to reduce free IL-18 to HC levels,
thus reflecting an imbalance which might favor a general
inflammatory state in the early phase of the disorder.
Noteworthy, in agreement with the condition we have
described for young SCZ patients, a number of studies
has previously reported disease-related high levels of free
IL-18, despite the concomitant over expression of IL-
18BP [10,22,23], which is in accordance with the nature
of the interaction between IL-18 and IL-18BP [24].
At variance with young individuals, SCZ subjects with
an age ≥50 years did not show levels of total IL-18 sig-
nificantly different from HC, likely a result of the age-
dependent increase of total IL-18 values occurring only
in HC, which would progressively bring the cytokine
levels of the latter to almost reach those of SCZ. Fur-
thermore, in older SCZ the highly significant elevation
of IL-18BP persisted and free IL-18 levels appeared
slightly lower than those of HC. In this view, a possible
modulation of IL-18 system might be envisaged accord-
ing to the following scenario. In young SCZ, total and
free IL-18 increase over normal levels, similar to what
has been observed for other pro-inflammatory cytokines,
perhaps as a consequence of an inflammatory challenge
at the maternal-fetal interface [14]. Therefore, IL-18BP
elevation might be interpreted as an effort of the organ-
ism to compensate the exaggerated inflammatory re-
sponse linked to the disorder. This counteraction might
become effective in balancing the IL-18-mediated pro-
inflammatory reaction only in the later stages.
In agreement with our findings, other recent studies
suggest that SCZ subjects are not characterized by a
simple pro-inflammatory profile, but more likely the ill-
ness is accompanied by both pro- and anti-inflammatory
activated forces, which may involve both monocyte and
T-cell networks, probably as a product of an inflamma-
tory system control [25,26]. Yet, the sense of this per-
turbation in IL-18 system, characterized by elevated
levels of IL-18BP here described for the first time in the
context of schizophrenia, should be deciphered on a
time-dependent basis, in the light of its ability to limit
harmful inflammation on the one hand and to contrib-
ute to increased susceptibility to infection and immune-
related diseases, on the other hand [27]. The early in-
crease in free IL-18, which fades away with age in SCZ,
consistently points to the importance of considering age
and duration of the illness when discussing the immune-
related pathophysiological mechanisms of schizophrenia.
Longitudinal studies that address the kinetic of IL-18
system players in relation to disease progression can fur-
ther clarify the role of free IL-18 in SCZ patients.
The interpretation of our results should take into con-
sideration some limitations of the present study. We used
a naturalistic approach where all SCZ were receiving psy-
chotropic drugs, though antipsychotic medication might
be a confounding factor in the analysis of the immune sys-
tem in schizophrenia. Nonetheless, in this study there was
not a relationship between antipsychotic treatment
dosages and the cytokine parameters, suggesting that in
our conditions treatment and serum IL-18 system changes
might be independent. This is consistent with the findings
of two other recent studies which report that the anti-
psychotic treatment does not significantly modulate the
levels of IL-18 in the serum of schizophrenic patients
[18,19], even though the cytokine produced by patients’
blood cells is actually increased by therapy [18]. In conclu-
sion, regardless of whether the IL-18 dysregulation is of
genetic, infectious or other origin, our findings strongly
suggest that the elevation of IL-18BP found in our SCZ, as
well as the whole perturbation of the IL-18 system, might
be indeed a specific phenomenon of schizophrenia. Given
the hypothesis of immune dysfunction in this illness and
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the emergent interest in inflammatory mechanisms as po-
tential targets for its treatment [27,28], our results may
offer new insights into the field. In fact, even though fur-
ther clarification of IL-18 role in the disease is certainly
needed, the described data suggest that more attention
should be paid to the analysis of circulating cytokines,
which ought to include the contextual measurement of
cytokine natural inhibitors and antagonists in order to de-
velop novel and potentially effective anti-inflammatory
therapeutic intervention against schizophrenia.
Abbreviations
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders;
ELISA: Enzyme-Linked Immunosorbent Assay; HC: healthy controls;
IL: interleukin; IL-18BP: interleukin-18 binding protein; SCZ: schizophrenia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
PB, GS and CC designed and coordinated the study. IAR, SF and GS selected
patients and performed all clinical evaluations. IP, FS and AC prepared samples
and performed cytokine experiments. All authors made substantial contribution
to analysis and discussion of the data. IP wrote the initial draft of the
manuscript and PB revised it. All authors made contributions in writing and
discussing the manuscript. All authors have read and approved its final version.
Acknowledgements
This study received financial support from Italian Ministry of Health, Grant
RF07-08 and RC-05-06-07-08-09-10-11 (PB and GS). This study was supported
by the ERANET-NEURON 2010 grant.
Author details
1Clinical and Behavioral Neurology, IRCCS Fondazione Santa Lucia,
Via Ardeatina 306, 00179 Rome, Italy. 2Department of Neuroscience,
University Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. 3Department of
Clinical and Behavioral Neurology, Experimental Neuro-psychobiology Lab,
IRCCS Santa Lucia Foundation, Via Ardeatina, 306, I-00179 Rome, Italy.
Received: 6 July 2012 Accepted: 13 August 2012
Published: 22 August 2012
References
1. Dinarello CA: Interleukin-18, a proinflammatory cytokine. Eur Cytokine
Netw 2000, 11:483–486.
2. Dinarello CA: Interleukin 1 and interleukin 18 as mediators of
inflammation and the aging process. Am J Clin Nutr 2006, 83:447S–455S.
3. Alboni S, Cervia D, Sugama S, Conti B: Interleukin 18 in the CNS.
J Neuroinflammation 2010, 7:9.
4. Bossù P, Salani F, Cacciari C, Picchetto L, Cao M, Bizzoni F, Rasura M,
Caltagirone C, Robinson RG, Orzi F, Spalletta G: Disease outcome,
alexithymia and depression are differently associated with serum IL-18
levels in acute stroke. Curr Neurovasc Res 2009, 6:163–170.
5. Bossù P, Ciaramella A, Salani F, Vanni D, Palladino I, Caltagirone C,
Scapigliati G: Interleukin-18, from neuroinflammation to Alzheimer’s
disease. Curr Pharm Des 2010, 16:4213–4224.
6. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M:
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine
response. Immunity 1999, 10:127–136.
7. Sims JE: IL-1 and IL-18 receptors, and their extended family. Curr Opin
Immunol 2002, 14:117–122.
8. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z,
Keane WF, Chvatchko Y, Kim SH, Fantuzzi G, Dinarello CA, Rubinstein M: A
novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and
extensive decrease of free IL-18. Cytokine 2001, 14:334–342.
9. Gangemi S, Basile G, Merendino RA, Minciullo PL, Novick D, Rubinstein M,
Dinarello CA, Lo Balbo C, Franceschi C, Basili S, D’ Urbano E, Daví G,
Nicita-Mauro V, Romano M: Increased circulating Interleukin-18 levels in
centenarians with no signs of vascular disease: another paradox of
longevity? Exp Gerontol 2003, 38:669–672.
10. Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM: High
circulating levels of free interleukin-18 in patients with active SLE in the
presence of elevated levels of interleukin-18 binding protein.
J Autoimmun 2010, 34:121–126.
11. Mühl H, Kämpfer H, Bosmann M, Frank S, Radeke H, Pfeilschifter J:
Interferon-gamma mediates gene expression of IL-18 binding protein in
nonleukocytic cells. Biochem Biophys Res Commun 2000, 267:960–963.
12. Kinney DK, Hintz K, Shearer EM, Barch DH, Riffin C, Whitley K, Butler R:
A unifying hypothesis of schizophrenia: abnormal immune system
development may help explain roles of prenatal hazards, post-pubertal
onset, stress, genes, climate, infections, and brain dysfunction. Med
Hypotheses 2010, 74:555–563.
13. Meyer U: Developmental neuroinflammation and schizophrenia. Prog
Neuropsychopharmacol Biol Psychiatry 2011, PMID: 22122877.
14. Watanabe Y, Someya T, Nawa H: Cytokine hypothesis of schizophrenia
pathogenesis: evidence from human studies and animal models.
Psychiatry Clin Neurosci 2010, 64:217–230.
15. Shirts BH, Wood J, Yolken RH, Nimgaonkar VL: Comprehensive Evaluation
of Positional Candidates in the IL-18 Pathway Reveals Suggestive
Associations With Schizophrenia and Herpes Virus Seropositivity.
Am J Med Genet B Neuropsychiatr Genet 2008, 147:343–350.
16. Liu J, Liu J, Zhou Y, Li S, Li Y, Song X, Wang J, Wang L, Ying B: Association
between promoter variants of interleukin-18 and schizophrenia in a Han
Chinese population. DNA Cell Biol 2011, 30:913–917.
17. Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M: Serum interleukin-18 levels
are elevated in schizophrenia. Psychiatry Res 2000, 96:75–80.
18. Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M,
Di Nicola M, Grilli A: Dysregulation of chemo-cytokine production in
schizophrenic patients versus healthy controls. BMC Neurosci 2011, 25:12–13.
19. Xiu MH, Chen DC, Wang D, Zhang K, Dong A, Tang W, Zhang F, Liu LJ,
Liu JH, Liu HB, Yang FD, Kosten TR, Zhang XY: Elevated interleukin-18
serum levels in chronic schizophrenia: association with
psychopathology. J Psychiatr Res 2012, 46:1093–1098.
20. Spoletini I, Cherubini A, Banfi G, Rubino IA, Peran P, Caltagirone C,
Spalletta G: Hippocampi, thalami, and accumbens microstructural
damage in schizophrenia: a volumetry, diffusivity, and
neuropsychological study. Schizophr Bull 2011, 37:118–130.
21. Migliorini P, Anzilotti C, Pratesi F, Quattroni P, Bargagna M, Dinarello CA,
Boraschi D: Serum and urinary levels of IL-18 and its inhibitor IL-18BP in
systemic lupus erythematosus. Eur Cytokine Netw 2010, 21:264–271.
22. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, Veit V,
Paul P, Rubinstein M, Dinarello CA, Harlé JR, Kaplanski G: Severe imbalance
of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome.
Blood 2005, 106:3483–3489.
23. Ludwiczek O, Kaser A, Novick D, Dinarello CA, Rubinstein M, Tilg H: Elevated
systemic levels of free interleukin-18 (IL-18) in patients with Crohn’s
disease. Eur Cytokine Netw 2005, 16:27–33.
24. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M,
Dinarello CA: Structural requirements of six naturally occurring isoforms
of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 2000,
97:1190–1195.
25. Drexhage RC, Hoogenboezem TA, Cohen D, Versnel MA, Nolen WA,
van Beveren NJ, Drexhage HA: An activated set point of T-cell and
monocyte inflammatory networks in recent-onset schizophrenia patients
involves both pro- and anti-inflammatory forces. Int J
Neuropsychopharmacol 2011, 14:746–755.
26. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of
cytokine alterations in schizophrenia: clinical status and antipsychotic
effects. Biol Psychiatry 2011, 70:663–671.
27. Meyer U: Anti-inflammatory signaling in schizophrenia. Brain Behav
Immun 2011, 25:1507–1518.
28. Meyer U, Schwarz MJ, Müller N: Inflammatory processes in schizophrenia:
a promising neuroimmunological target for the treatment of negative/
cognitive symptoms and beyond. Pharmacol Ther 2011, 132:96–110.
doi:10.1186/1742-2094-9-206
Cite this article as: Palladino et al.: Elevated levels of circulating IL-18BP
and perturbed regulation of IL-18 in schizophrenia. Journal of
Neuroinflammation 2012 9:206.
Palladino et al. Journal of Neuroinflammation 2012, 9:206 Page 5 of 5
http://www.jneuroinflammation.com/content/9/1/206
